Top News arrow Whistleblowers
Whistleblowers Break the Silence
Avandia, a Case of Deja Vu all over again Print E-mail
Saturday, 20 February 2010

Even worse, FDA officials, in collusion and collaboration with GSK, approved an unethical and exploitative clinical trialTIDE, which is on-going.

Read more...
 
Criminal Drug Marketing Remains an Issue Print E-mail
Friday, 29 January 2010
Read more...
 
BMJ Demands Raw Data From Pharma Clinical Trials Print E-mail
Friday, 11 December 2009
The system has provided companies an opportunity to make spectacular profits from the widespread use of defective drugs and vaccines that have caused irreversible harm.
Read more...
 
BIG PHARMA’S CRIME SPREE Print E-mail
Wednesday, 02 December 2009
Rather than having a deterrent effect, the number of Big Pharma high profile criminal settlements is increasing and the settlements are getting bigger.
Read more...
 
Follow-up: Antipsychotics--Psychiatry's Disregard for the life-threatening hazards Print E-mail
Saturday, 31 October 2009
Corporate business ethics and investors’ interests have swept aside the humanitarian foundation of American medicine and most of related healthcare, and caring service professions.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 19 - 27 of 136
(C) 2012 Alliance for Human Research Protection
CMS installation and website development by Anne Krauss

General Terms & Disclaimer:

This site is not a monologue of truth. It is a catalyst for public debate about medical research conduct. The reader is urged to confront officials to clarify issues mentioned herein. This site is designed strictly to provide information for critical, literary, academic an public usage. A qualified and trustworthy medical professional must be consulted regarding medical issues, treatments, diagnoses, etc.

Please read the General Terms and Conditions of this agreement entirely and carefully before accessing this web site. By accessing the site, you agree to be bound by the terms and conditions listed herein. [continue]